AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AIM ImmunoTech Inc. (AIM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.13

-0.01 (-6.20%)

At close: Feb 14, 2025, 3:59 PM

0.13

1.23%

After-hours Feb 14, 2025, 05:14 PM EST

undefined% (undefined)

Bid	n/a
Market Cap	8.97M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.47
PE Ratio (ttm)	-0.28
Forward PE	n/a
Analyst	Buy

Ask	0.13
Volume	2,058,286
Avg. Volume (20D)	994,168
Open	0.14
Previous Close	0.14
Day's Range	0.12 - 0.14
52-Week Range	0.12 - 0.62
Beta	undefined

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, n...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 12, 1996

Employees 26

Stock Exchange AMEX

Ticker Symbol AIM

Website https://www.aimimmuno.com

Analyst Forecast

According to 2 analyst ratings, the average rating for AIM stock is "Buy." The 12-month stock price forecast is $2.75, which is an increase of 2007.28% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AIM ImmunoTech Inc. is scheduled to release its earnings on Apr 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 days ago

+5.84%

AIM ImmunoTech shares are trading higher after the... Unlock content with Pro Subscription

5 months ago

-2.45%

AIM ImmunoTech shares are trading higher after the company announced preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi.

News

1 week ago · proactiveinvestors.co.uk

KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said ...

2 weeks ago · proactiveinvestors.co.uk

Polarean Imaging inks partnership with US outpatient medical imaging firm

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) is teaming up with SimonMed Imaging, one of America's largest outpatient medical imaging providers. It will see the AIM-quoted firm's Xenon MRI platform deli...

1 month ago · zacks.com

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?

AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · proactiveinvestors.co.uk

Deltex Medical shares plunge 50% on proposed AIM cancellation and CEO resignation

Shares in Deltex Medical Group plc (AIM:DEMG) (AIM: DEMG) fell 50% following the announcement of a proposed delisting from AIM and leadership changes. The company attributed its decision to delist to ...

2 months ago · businesswire.com

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elec...

2 months ago · businesswire.com

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders...

2 months ago · businesswire.com

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

2 months ago · proactiveinvestors.co.uk

Eden Research's regulatory wins keep coming at breakneck pace

Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't ...

2 months ago · businesswire.com

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recomme...

2 months ago · proactiveinvestors.co.uk

SDX Energy shares plunge on London delisting plan

SDX Energy PLC (AIM:SDX, OTC:SDXEF) shares plunged around 60% in value on Friday as it announced it intends to exit the London Stock Exchange, delisting from AIM to take up private company status. It ...

Load More News